Video

Dr. Marks on how PSMA imaging is “opening doors” in prostate cancer

Author(s):

Urology Times staff

“We call this a ‘disruptive innovation,’” says Leonard S. Marks, MD.

In this video, Leonard S. Marks, MD, explains how the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer will affect urologists and patients alike. Marks is a deKernion Endowed Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles.

Related Videos
Wayne Kuang, MD, answers a question during a Zoom video interview
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Mohamad Baker Berjaoui, MD, answers a question during a Zoom video interview
Related Content
PSMA-PET shows diagnostic accuracy in initial staging of prostate cancer
December 20th 2024

PSMA-PET shows diagnostic accuracy in initial staging of prostate cancer

Hannah Clarke
The investigators found a positive correlation between PSA levels and SUVmax.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Enrollment goal met in phase 3 SOLAR-RECUR trial
November 22nd 2024

Enrollment goal met in phase 3 SOLAR-RECUR trial

Hannah Clarke
The trial is evaluating the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer following treatment with curative intent.
Head-to-head trial to compare 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT
November 19th 2024

Head-to-head trial to compare 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT

Hannah Clarke
The primary objective is to compare the detection rate of sites of prostate cancer recurrence between the 2 agents.
Collaboration to support phase 3 SECuRE trial of 67Cu-SAR-bisPSMA
November 12th 2024

Collaboration to support phase 3 SECuRE trial of 67Cu-SAR-bisPSMA

Hannah Clarke
The phase 1/2a SECuRE trial is evaluating the safety and efficacy of 67Cu-SAR-bisPSMA in the treatment of patients with mCRPC.
Study to inform definitive trial of 99mTc-sestaMIBI SPECT/CT for T1 renal tumors
November 12th 2024

Study to inform definitive trial of 99mTc-sestaMIBI SPECT/CT for T1 renal tumors

Hannah Clarke
The sensitivity of 99mTc-sestaMIBI SPECT/CT was 97%, and the specificity was 53.8%.
© 2024 MJH Life Sciences

All rights reserved.